ALX Oncology Holdings Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Hey, good morning, everyone. My name is Daniel Wolle. I'm an analyst covering smid-cap biotech. Welcome to the 40th Annual JPM Healthcare Conference. I'm joined today with President and CEO, Jaume Pons, of ALX Oncology. As a reminder, if you want to ask questions, you can submit using the blue Ask a Question button to the question portal and I'll be able to ask those questions. Without further ado, Jaume?
Thank you, Daniel. After the customary disclaimers on Slide #1, let's move to Slide #2. Our main focus is evorpacept, a highly differentiated CD47 blocker that is now in Phase II clinical trials for 3 solid tumor indications and ASPEN early clinical studies in 2 heme indications. Evorpacept is designed to be used in combination with a long list of anticancer therapies. So if we are successful, it can be a cornerstone of therapy. Evorpacept was designed to be used on top of the standard of care in combination.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
